Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury

Matthew L. Stone, Ashish K. Sharma, Yunge Zhao, Eric J. Charles, Mary E. Huerter, William F. Johnston, Irving L. Kron, Kevin R. Lynch, Victor E. Laubach

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Outcomes for lung transplantation are the worst of any solid organ, and ischemia-reperfusion injury (IRI) limits both short- and long-term outcomes. Presently no therapeutic agents are available to prevent IRI. Sphingosine 1-phosphate (S1P) modulates immune function through binding to a set of G protein-coupled receptors (S1PR1-5). Although S1P has been shown to attenuate lung IRI, the S1P receptors responsible for protection have not been defined. The present study tests the hypothesis that protection from lung IRI is primarily mediated through S1PR1 activation. Mice were treated with either vehicle, FTY720 (a nonselective S1P receptor agonist), or VPC01091 (a selective S1PR1 agonist and S1PR3 antagonist) before left lung IR. Function, vascular permeability, cytokine expression, neutrophil infiltration, and myeloperoxidase levels were measured in lungs. After IR, both FTY720 and VPC01091 significantly improved lung function (reduced pulmonary artery pressure and increased pulmonary compliance) vs. vehicle control. In addition, FTY720 and VPC01091 significantly reduced vascular permeability, expression of proinflammatory cytokines (IL-6, IL-17, IL-12/IL-23 p40, CC chemokine ligand-2, and TNF-a), myeloperoxidase levels, and neutrophil infiltration compared with control. No significant differences were observed between VPC01091 and FTY720 treatment groups. VPC01091 did not significantly affect elevated invariant natural killer T cell infiltration after IR, and administration of an S1PR1 antagonist reversed VPC01091- mediated protection after IR. In conclusion, VPC01091 and FTY720 provide comparable protection from lung injury and dysfunction after IR. These findings suggest that S1P-mediated protection from IRI is mediated by S1PR1 activation, independent of S1PR3, and that selective S1PR1 agonists may provide a novel therapeutic strategy to prevent lung IRI.

Original languageEnglish (US)
Pages (from-to)1245-1252
Number of pages8
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume308
Issue number12
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Lysosphingolipid Receptors
Reperfusion Injury
Lung
Neutrophil Infiltration
Capillary Permeability
Peroxidase
Cytokines
Interleukin-23
Lung Compliance
CC Chemokines
Natural Killer T-Cells
Lung Transplantation
Interleukin-17
Lung Injury
Interleukin-12
G-Protein-Coupled Receptors
rac-((1R*,3S*)-1-amino-3-(4-octylphenyl)cyclopentyl)methanol hydrochloride
Pulmonary Artery
Interleukin-6
Fingolimod Hydrochloride

Keywords

  • Barrier function
  • Inflammation
  • Invariant natural killer T cells
  • Lung transplantation
  • Primary graft dysfunction

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

Stone, M. L., Sharma, A. K., Zhao, Y., Charles, E. J., Huerter, M. E., Johnston, W. F., ... Laubach, V. E. (2015). Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 308(12), 1245-1252. https://doi.org/10.1152/ajplung.00302.2014

Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury. / Stone, Matthew L.; Sharma, Ashish K.; Zhao, Yunge; Charles, Eric J.; Huerter, Mary E.; Johnston, William F.; Kron, Irving L.; Lynch, Kevin R.; Laubach, Victor E.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 308, No. 12, 01.01.2015, p. 1245-1252.

Research output: Contribution to journalArticle

Stone, ML, Sharma, AK, Zhao, Y, Charles, EJ, Huerter, ME, Johnston, WF, Kron, IL, Lynch, KR & Laubach, VE 2015, 'Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 308, no. 12, pp. 1245-1252. https://doi.org/10.1152/ajplung.00302.2014
Stone, Matthew L. ; Sharma, Ashish K. ; Zhao, Yunge ; Charles, Eric J. ; Huerter, Mary E. ; Johnston, William F. ; Kron, Irving L. ; Lynch, Kevin R. ; Laubach, Victor E. / Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2015 ; Vol. 308, No. 12. pp. 1245-1252.
@article{ab9d6d8266bb4b7487bf4d9f7910faa0,
title = "Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury",
abstract = "Outcomes for lung transplantation are the worst of any solid organ, and ischemia-reperfusion injury (IRI) limits both short- and long-term outcomes. Presently no therapeutic agents are available to prevent IRI. Sphingosine 1-phosphate (S1P) modulates immune function through binding to a set of G protein-coupled receptors (S1PR1-5). Although S1P has been shown to attenuate lung IRI, the S1P receptors responsible for protection have not been defined. The present study tests the hypothesis that protection from lung IRI is primarily mediated through S1PR1 activation. Mice were treated with either vehicle, FTY720 (a nonselective S1P receptor agonist), or VPC01091 (a selective S1PR1 agonist and S1PR3 antagonist) before left lung IR. Function, vascular permeability, cytokine expression, neutrophil infiltration, and myeloperoxidase levels were measured in lungs. After IR, both FTY720 and VPC01091 significantly improved lung function (reduced pulmonary artery pressure and increased pulmonary compliance) vs. vehicle control. In addition, FTY720 and VPC01091 significantly reduced vascular permeability, expression of proinflammatory cytokines (IL-6, IL-17, IL-12/IL-23 p40, CC chemokine ligand-2, and TNF-a), myeloperoxidase levels, and neutrophil infiltration compared with control. No significant differences were observed between VPC01091 and FTY720 treatment groups. VPC01091 did not significantly affect elevated invariant natural killer T cell infiltration after IR, and administration of an S1PR1 antagonist reversed VPC01091- mediated protection after IR. In conclusion, VPC01091 and FTY720 provide comparable protection from lung injury and dysfunction after IR. These findings suggest that S1P-mediated protection from IRI is mediated by S1PR1 activation, independent of S1PR3, and that selective S1PR1 agonists may provide a novel therapeutic strategy to prevent lung IRI.",
keywords = "Barrier function, Inflammation, Invariant natural killer T cells, Lung transplantation, Primary graft dysfunction",
author = "Stone, {Matthew L.} and Sharma, {Ashish K.} and Yunge Zhao and Charles, {Eric J.} and Huerter, {Mary E.} and Johnston, {William F.} and Kron, {Irving L.} and Lynch, {Kevin R.} and Laubach, {Victor E.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1152/ajplung.00302.2014",
language = "English (US)",
volume = "308",
pages = "1245--1252",
journal = "American Journal of Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "12",

}

TY - JOUR

T1 - Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury

AU - Stone, Matthew L.

AU - Sharma, Ashish K.

AU - Zhao, Yunge

AU - Charles, Eric J.

AU - Huerter, Mary E.

AU - Johnston, William F.

AU - Kron, Irving L.

AU - Lynch, Kevin R.

AU - Laubach, Victor E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Outcomes for lung transplantation are the worst of any solid organ, and ischemia-reperfusion injury (IRI) limits both short- and long-term outcomes. Presently no therapeutic agents are available to prevent IRI. Sphingosine 1-phosphate (S1P) modulates immune function through binding to a set of G protein-coupled receptors (S1PR1-5). Although S1P has been shown to attenuate lung IRI, the S1P receptors responsible for protection have not been defined. The present study tests the hypothesis that protection from lung IRI is primarily mediated through S1PR1 activation. Mice were treated with either vehicle, FTY720 (a nonselective S1P receptor agonist), or VPC01091 (a selective S1PR1 agonist and S1PR3 antagonist) before left lung IR. Function, vascular permeability, cytokine expression, neutrophil infiltration, and myeloperoxidase levels were measured in lungs. After IR, both FTY720 and VPC01091 significantly improved lung function (reduced pulmonary artery pressure and increased pulmonary compliance) vs. vehicle control. In addition, FTY720 and VPC01091 significantly reduced vascular permeability, expression of proinflammatory cytokines (IL-6, IL-17, IL-12/IL-23 p40, CC chemokine ligand-2, and TNF-a), myeloperoxidase levels, and neutrophil infiltration compared with control. No significant differences were observed between VPC01091 and FTY720 treatment groups. VPC01091 did not significantly affect elevated invariant natural killer T cell infiltration after IR, and administration of an S1PR1 antagonist reversed VPC01091- mediated protection after IR. In conclusion, VPC01091 and FTY720 provide comparable protection from lung injury and dysfunction after IR. These findings suggest that S1P-mediated protection from IRI is mediated by S1PR1 activation, independent of S1PR3, and that selective S1PR1 agonists may provide a novel therapeutic strategy to prevent lung IRI.

AB - Outcomes for lung transplantation are the worst of any solid organ, and ischemia-reperfusion injury (IRI) limits both short- and long-term outcomes. Presently no therapeutic agents are available to prevent IRI. Sphingosine 1-phosphate (S1P) modulates immune function through binding to a set of G protein-coupled receptors (S1PR1-5). Although S1P has been shown to attenuate lung IRI, the S1P receptors responsible for protection have not been defined. The present study tests the hypothesis that protection from lung IRI is primarily mediated through S1PR1 activation. Mice were treated with either vehicle, FTY720 (a nonselective S1P receptor agonist), or VPC01091 (a selective S1PR1 agonist and S1PR3 antagonist) before left lung IR. Function, vascular permeability, cytokine expression, neutrophil infiltration, and myeloperoxidase levels were measured in lungs. After IR, both FTY720 and VPC01091 significantly improved lung function (reduced pulmonary artery pressure and increased pulmonary compliance) vs. vehicle control. In addition, FTY720 and VPC01091 significantly reduced vascular permeability, expression of proinflammatory cytokines (IL-6, IL-17, IL-12/IL-23 p40, CC chemokine ligand-2, and TNF-a), myeloperoxidase levels, and neutrophil infiltration compared with control. No significant differences were observed between VPC01091 and FTY720 treatment groups. VPC01091 did not significantly affect elevated invariant natural killer T cell infiltration after IR, and administration of an S1PR1 antagonist reversed VPC01091- mediated protection after IR. In conclusion, VPC01091 and FTY720 provide comparable protection from lung injury and dysfunction after IR. These findings suggest that S1P-mediated protection from IRI is mediated by S1PR1 activation, independent of S1PR3, and that selective S1PR1 agonists may provide a novel therapeutic strategy to prevent lung IRI.

KW - Barrier function

KW - Inflammation

KW - Invariant natural killer T cells

KW - Lung transplantation

KW - Primary graft dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84932139889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932139889&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00302.2014

DO - 10.1152/ajplung.00302.2014

M3 - Article

C2 - 25910934

AN - SCOPUS:84932139889

VL - 308

SP - 1245

EP - 1252

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 1040-0605

IS - 12

ER -